Corel Medical Series: Cancer/Corel Medical Series: Cancer.iso/mac/Program/Indexdat/indexa.C

Text File | 1997-01-27 | 9KB | 2 lines

Cadmium,p01.7;p34.7,Camptothecin,p35.8;p35.14,Cancer,15,Cancer Act,p33.8;p33.12,Cancer of an unknown primary site (CUPS),7,Cancer Therapy Evaluation Program,p35.7,CancerFax,p37.17,CancerNet,p37.18,Cancervive,p31.10,Canes,p26.5,Capillary leak syndrome,p08.17,Carafate,p17.18;p18.15,Carbamazepine,c05.26,Carboplatin,12,Carboplatinum,c18.18,Carcinogen,2,Carcinogenic bullet theory,p01.7,Carcinoid tumor,5,Carcinoma,15,Carcinosarcoma,3,Carmustine,c17.10;c17.17;c28.12,Carnation Breakfast Drink,p17.19,Cascara sagrada,p17.24,Castor oil,p17.24,Cataracts,p12.10,Catheters,p05.7;p05.9;p05.10;p07.10;p07.11;p07.12,CAUTION (Seven Early Warning Signals),p02.2,Celiac disease,c38.3,Cell salvage,p14.11,Cellothyl,p17.24,Cells,2,Cellulitis,p20.3,Centers for Disease Control and Prevention,p34.23,Central nervous system,3,Cerebral neuroblastoma,c10b.20,Cervical cancer,11,Cervical conization,c09.15;c09.17,Chemoembolization,c08.13;c15.10;c19.12;c27.12,Chemotherapy,15,Chief cell cancer parathyroid,c32.2,Childhood cancer,17,Children talking with,p16.6;p27.10,The Children's Cancer Group,c10a.12;c10a.15;c10b.1;c10b.8,Chills,p08.17;p20.5,Chlamydia,c02.3,Chlorambucil,chr.p17.13;c23.17;c24.16,2-Chlorodeoxyadenosine,c18.18;c18.28;c24.17,Chloroma,c18.4,Chlorpromazine,c08.8,Cholangiocarcinoma,c19.1,Cholangitis,c03.6,Choledochal cysts,c03.3,Cholestyramine,p17.31;c03.17,Chondrosarcoma,c10a.2;c35.33;c36.2;chr.c36.2.,Chorioadenoma destruens,c43.1,Choriocarcinoma,c07.1;c07.6;c30.1,Choroid plexus tumor child,c10b.2,Chromophobe adenoma,c34.1;c34.7,Chromosomes,p01.1;p12.5,Chronic leukemia,5,Chronulac,p17.25,Cigna Health Plans,p32a.6,Ciprofloxicin,p20.9,Circumcision,c33.1;c33.2,Cirrhosis of liver,c19.4,Cisplatin,11,cancer,13,13-Cis-retinoic acid,c14a.5,Citoein,p17.28,Classic seminoma testis cancer,c40.1,Clear cell tumor,4,Clinical physicist,p06.4,Clinical trials,9,Cloacogenic cancer,c02.1,Clonigenic assay,p07.17,Coal-tar products,p01.7;p34.7,Cobalt 60 equipment,p06.7,Codeine,p17.23;p19.8;p19.9;p23.8;p27.6,Colace,p17.25,Colitis,p05.3;c03.3;c11a.4;c41.2,Colon cancer,17,Colonoscopy,p02.17;c11b.22,Colony-stimulating factor (CSF),11,Colostomy,5,Colostomy pouch,p21.7,Combination therapy,9,Commode chair,p26.5,Communication,3,Compazine,p17.14;chr.p17.14;p18.20;c18.17,Computerized tomography (CT),p01.3;p02.13,Connective tissue disorders 612 ,0,Consensus Conference on Colon and Rectal Cancer,c11c.16,Constipation,4,Consumer Reports Health Letter,p13.14,Contrast agents,p02.12;p06.4,Cortical adenoma,c01.2,Corticosteroids,c08.8,The Cosmetic Toiletry and Fragrance Association (CTFA) Foundation,p22.4,Cosmetician,p03.6,Costs,4,Coughing,p20.5,Counselor,p03.5,Cramps,p06.18,Craniopharyngioma child,c10b.2;c10b.17,Creme de la Femme,p23.5,Crohn's disease,c11a.4;c38.4,Crutches,p26.5,Cryosurgery,c19.11;c19.15;c27.13;c35.15;c37.14,Cryotherapy,c09.15;c10c.4;c33.12,Cryptorchidism,c40.4,Curettage and electrodesiccahon (C&E),c37.13,Cushing's disease,c01.1;c01.5;c01.6;c21.2;c34.1,Cyclophosphamide,17,Cyclosporin A analogues,p35.18,Cyclosporine,c28.14,Cystadenocarcinoma,c31.1,Cystectomy,c04.12;c04.17;c04.20;c04.22;c04.23,Cystitis,c04.2,Cystosarcoma phylloides,c06.3,Cytadren,c06.26;c06.42;c06.47,Cytarabine,chr.p17.13;p35.19,Cytokines,p08.3;p08.4;p08.6;p08.7;p08.8;p08.11;p08.17;p17.4;p35.11;p35.19;c18.14,Cytological studies,p02.19,Cytomegalovirus,c16.3,Cytosar,chr.p17.13;c18.13;c18.17;c18.18,Cystoscopy,p02.17,Cytosine arabinoside,c18.13;c18.17;c24.19;c24.20,Cytoxan,11,
advocacy against,p34.25,causes,p01.5,diagnosing,p02.1,early detection,p34.2;p34.17,growth,p01.2,living with,p16.1;p28.1;p29.1,myths,p31.7,prevention,p33.9;p34.2;p34.11;p34.23,risk assessment,p34.20,risk factors,p34.5,screening,p34.20,spreading,p01.10,staging,p01.17,surviving,p31.1,symptoms,p02.3,defined,c07.1,diagnosis,c07.5,diagram,c07.4,pathologic methods,c07.8,site locating,c07.3,staging,c07.11,treatment,c07.12,clinical trials,p35.4,for bladder cancer,c04.24,for brain tumor,c10b.16;c10b.18,for cervical cancer,c09.19;c09.22;c09.24,for lung cancer,c20.18,for ovarian cancer,c29.13;c29.16;c29.17;c29.18;c29.19;c29.20;c29.21;c29.24;c30.12;c30.13;c30.14;c30.16;c30.18,for stomach cancer,c39.16,for testis cancer,c40.17;c40.18;c40.23,for uterine cancer,c44.13;c44.16;c44.17;c44.19;c44.20;c44.21,for vaginal cancer,c46.12;c46.13;c46.15,for vulvar cancer,c47.14;c47.15,side effects,chr.p17.13,defined,p01.7,environmental,p34.7,appendiceal,c08.9,colorectal,c11a.2,rectal,c08.9,small bowelc0810, ,small intestine,c38.2;c38.13,adrenocortical,c01.2;c01.9;c01.10;c01.12,anaplastic,c42.23,basal cell,c37.1;c37.2;c37.19;c47.2;c47.18,defined,p01.12,ductal,c06.3;c35.32,embryonal,c30.1;c40.2,endometrial,c29.1;c35.32;c44.1,epidermoid,c07.4;c07.13;c42.2,islet cell,c15.1,medullary,c06.4;c42.3;c42.22,musinous,c06.2;c06.4;c29.2,scirrhous,c39.2,small cell,c02.2;c31.1,transitional cell,c02.1;c04.2;c35.32,treatment,p12.23;p12.24,breast,c06.3,prostate,c35.33,uterus,c45.2,cancerous,p01.1,healthy,p01.1,drug delivery to,p07.11,lymphoma,c05.2;c05.20,metastatic cancer,c05.21,causes,c09.3,diagnosis,c09.9,follow-up,c09.23,questions to ask,c09.25,recurrence,c09.24,risk factors,c09.5,screening,c09.7,spread,c09.2,symptoms,c09.8,treatment,c09.12,types,c09.1,adjuvant,p04.6,blood count monitoring,p07.22,dosage,p07.19,drug selechon,p07.16,duration,p07.14,goals,p07.3,high-dose,p07.20;p11.2,how it works,p07.6,in combinahon therapy,p04.6;p07.15;p09.11;p10.3;p12.17,methods,p05.7;p07.9,ovarian cancer (diagram),c29.14,range of drugs,p07.2,response measurement,p07.21,side effects,p07.24;p19.5,treatment option,p04.4,bone,c10d.1,brain tumor,c10b.1,causes,c10a.3,clinical trials,c10a.12;c10b.9,diagnosis,c10a.9,follow-up,c10a.18,questions to ask,c10a.19,retinoblastoma,p36.6;c10c.1,risk factors,c10a.5,screening,c10a.6,soft tissue,c10d.1,solid tumor,p12.24,special problems,c10a.23,staging,c10a.11,symptoms,c10a.7,treatment,c10a.12,types,c10a.1,defined,c18.3,granulocytic,c10a.1,lymphocytic,c18.9;c18.22,myelogenous,c18.23,treatment,c18.21,for adrenocortical carcinoma,c01.14,for anal cancer,c02.9;c02.13;c02.14;c02.17;c02.19,for bladder cancer,c04.20;c04.21;c04.22;c04.24,for brain tumor,c10b.13;c10b.16;c10b.18,for cervical cancer,c09.19;c09.22;c09.24,for esophageal cancer,c12.13;c12.14;c12.17;c12.18;c12.19;c12.20,for head and neck cancer,c14a.1;c14b.19;c14b.42,for lung cancer,c20.10;c20.18;c21.13,for lymphoma,c24.20,for mesothelioma,c26.11;c26.15,for ovarian,0,for pancreatic cancer,c31.11,for small intestine cancer,c38.12,for stomach cancer,c39.15;c39.16;c39.25,for testis cancer,c40.17;c40.18;chr.c40.17,for thymus cancer,c41.10,for trophoblastic disease,c43.15,for uterine cancer,c44.13;c44.16;c44.17;c44.19;c44.20;c44.21;c45.10;c45.12,for vaginal cancer,c46.10;c46.12;c46.13;c46.15,for vulvar cancer,c47.9;c47.11;c47.13;c47.14;c47.15,in hyperthermia,p10.3,in hyperthermic perfusion,p11.5,investigational,p35.4;p35.13,side effects,p17.4;chr.p17.13;p18.9,endometrium,c44.2,epithelium,c29.2,parathyroid,c32.2,skin,c25.5,childhood cancers,c10a.12;c10b.9,defined,p04.16,drugs used,p04.20,importance,p04.17,insurance coverage,p32a.12,participating in,p37.11,phases,p04.18;p35.3;p37.9,safety,p04.17,searching for,p37.8,causes,c11a.2,diagnosis,c11a.9,diagrams,c11a.6;c11b.4,follow-up,c11b.22,investigational drugs,p35.9;p35.10;p35.13,prophylactic surgery,p05.3,questions to ask,c11b.26,recurrence,c11b.24,risk factors,c11a.4,screening,c11a.6,and sexuality,p23.6,spread,c11a.2,staging,c11a.12,symptoms,c11a.8,treatment,p09.7;c11a.13;c11b.1;c11b.4;c11c.1;c11c.5,types,c11a.2,unknown primary site,p07.7,for bladder cancer,c04.24,for breast cancer,c06.28;c06.42,for colorectal cancer,c11b.25,for Kaposi's sarcoma,c16.19,for leukemia,c18.14;c18.18,for Iymphoma,c22.9,for multiple myeloma,c28.14,in biological therapy,p08.9,in bone marrow transplantation,p12.11,in chemotherapy,p07.23,to avoid infection,p20.9,adjusting to,p21.4,defined,p21.3,illustration,p21.4,procedure,p21.4,types,p21.5,biological therapy,p08.7,bone marrow transplantation,p12.3,chemotherapy,p04.6;p07.15;p09.11;p10.3;p12.17,and hair loss,p17.38,hyperthermia,p06.13;p10.3,laser therapy,p09.11,radiation therapy,p04.6;p07.15;p09.7;p09.11;p10.3;p12.17,surgery,p05.6;p05.7,types,p04.6,with doctor,p03.9;p03.13;p03.18;p23.16;p30.7,with family,p16.3;p23.12;p23.17;p26.15;p27.10;p30.4,with friends,p16.3;p30.5,causes,p17.23,defined,p17.23,home care,p26.8,relieving,p17.24,common terms,p32a.13,death,p32.6,home care,p26.7,insurance coverage,p32a.1;p32a.16,for adrenal gland cancer,c01.16,for bladder cancer,c04.4,for bone and soft tissue sarcomas,c36.11;c36.12;c36.13,for brain tumor,c10b.14;c10b.18,for breast cancer,c06.48,for Ewings sarcoma,c10d.11,for head and neck cancer,c14b.17;c14b.19,for leukemia,c18.23,for lung cancer,c21.13,for mesothelioma,c26.11;c26.16,for multiple myeloma,c28.12;c28.14,for osteogenic sarcoma,c10d.8,for parathyroid cancer,c32.11,for rhabdomyosarcoma,c10d.6,for testis cancer,chr.c40.17,in hyperthermia,p10.3,investigational,p35.4,for breast cancer,c06.24;c06.37;c06.39,for islet cell carcinoma,c15.10;c15.12,for leukemia,c18.19;c18.22;c18.23,for lymphoma,c22.7;c24.16;c24.18;c24.19;c24.20;c24.21,for ovarian cancer,c29.13;c29.16;c29.17;c29.18;c29.19;c29.20;c29.21;c30.14;c30.18,for thymus cancer,c41.10,for trophoblastic disease,c43.14;c43.15,for uterine cancer,c44.13;c44.16;c44.17;c44.19;c44.20;c44.21;c45.10;c45.12;c45.14;c45.16,for vulvar cancer,c47.9,risk factor,c04.6,side effects,chr.p17.13;p17.38,